Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $52.80 Average Target Price from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $52.80.

Several equities research analysts have recently commented on COLL shares. HC Wainwright restated a “buy” rating and set a $60.00 price target (up previously from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Truist Financial set a $55.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, January 7th. Needham & Company LLC boosted their price target on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th.

Collegium Pharmaceutical Trading Up 1.5%

Shares of Collegium Pharmaceutical stock opened at $47.61 on Thursday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. The company has a market capitalization of $1.50 billion, a P/E ratio of 29.57 and a beta of 0.64. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The company’s fifty day moving average is $47.40 and its two-hundred day moving average is $40.70.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.89 by $0.36. The business had revenue of $209.36 million during the quarter, compared to the consensus estimate of $191.25 million. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business’s quarterly revenue was down 18.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.61 earnings per share. Analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other news, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This trade represents a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares in the company, valued at $4,991,038.21. This represents a 14.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Illinois Municipal Retirement Fund grew its position in Collegium Pharmaceutical by 1.6% during the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock worth $605,000 after buying an additional 278 shares during the period. Vident Advisory LLC boosted its stake in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after acquiring an additional 281 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Collegium Pharmaceutical by 9.6% during the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 285 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 318 shares during the period. Finally, Federated Hermes Inc. increased its stake in Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.